Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Yoo, Hae Won | - |
dc.contributor.author | Park, Jun Yong | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Lee, Sae Hwan | - |
dc.contributor.author | Kim, Moon Young | - |
dc.contributor.author | Jun, Dae Won | - |
dc.contributor.author | Jang, Jae Young | - |
dc.contributor.author | Lee, Jin Woo | - |
dc.contributor.author | Kwon, Oh Sang | - |
dc.date.accessioned | 2022-02-06T01:40:16Z | - |
dc.date.available | 2022-02-06T01:40:16Z | - |
dc.date.created | 2022-01-20 | - |
dc.date.issued | 2022-01 | - |
dc.identifier.issn | 2045-2322 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/83439 | - |
dc.description.abstract | We prospectively investigated the changes of liver stiffness (LS) and the occurrence of hepatocellular carcinoma (HCC) after hepatitis C virus (HCV) eradication using direct antiviral agents (DAA) over three years. LS measurement using transient elastography and serum fibrosis surrogate markers before treatment and at 48, 96, 144 weeks after starting direct-acting antivirals (DAA) according to the protocol were evaluated. Patients were also compared with historical cohort treated with pegylated interferon (peg-IFN). Sustained viral response (SVR) was observed in 95.8%. LS value in the patients achieving SVR significantly decreased over time (19.4 ± 12.9 kPa [baseline], 13.9 ± 9.1 kPa [48 weeks], 11.7 ± 8.2 kPa [96 weeks], 10.09 ± 6.23 [144 weeks], all p < 0.001). With matched analysis, the decrease in LS value was significantly larger in DAA group than peg-IFN group at both 48 weeks (29% vs. 9%) and 96 weeks (39% vs. 17%). The incidence of HCC was not significantly different between DAA and peg-IFN groups (5.5% vs. 5.4%) at 144 weeks. HCV eradication with DAA can lead to improvement of liver stiffness over time. The regression of fibrosis was greater in the group with DAA than peg-IFN. Clinical trials registration: ClinicalTrials.gov (NCT02865369). © 2022, The Author(s). | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | Nature Research | - |
dc.relation.isPartOf | Scientific Reports | - |
dc.title | Regression of liver fibrosis and hepatocellular carcinoma development after HCV eradication with oral antiviral agents | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000740510500017 | - |
dc.identifier.doi | 10.1038/s41598-021-03272-1 | - |
dc.identifier.bibliographicCitation | Scientific Reports, v.12, no.1 | - |
dc.description.isOpenAccess | N | - |
dc.identifier.scopusid | 2-s2.0-85122696712 | - |
dc.citation.title | Scientific Reports | - |
dc.citation.volume | 12 | - |
dc.citation.number | 1 | - |
dc.contributor.affiliatedAuthor | Kwon, Oh Sang | - |
dc.type.docType | Article | - |
dc.subject.keywordPlus | CHRONIC HEPATITIS-C | - |
dc.subject.keywordPlus | SIMPLE NONINVASIVE INDEX | - |
dc.subject.keywordPlus | TRANSIENT ELASTOGRAPHY | - |
dc.subject.keywordPlus | DIAGNOSTIC-ACCURACY | - |
dc.subject.keywordPlus | THERAPY | - |
dc.subject.keywordPlus | CIRRHOSIS | - |
dc.subject.keywordPlus | STIFFNESS | - |
dc.subject.keywordPlus | VIRUS | - |
dc.subject.keywordPlus | PREDICT | - |
dc.subject.keywordPlus | TESTS | - |
dc.relation.journalResearchArea | Science & Technology - Other Topics | - |
dc.relation.journalWebOfScienceCategory | Multidisciplinary Sciences | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.